新型抗心力衰竭药物可溶性鸟苷酸环化酶刺激剂的获益证据及相关机制研究进展  

Research Progress on Benefit Evidence and Related Mechanisms of Novel Anti-Heart Failure Drug Soluble Guanylate Cyclase Stimulator

作　　者：王聪颖 冯露 孙鑫 陈淑霞[3] 王立立[3] 谷剑[3] WANG Congying;FENG Lu;SUN Xin;CHEN Shuxia;WANG Lili;GU Jian(Graduate School of Hebei North University,Zhangjiakou 075000,China;Graduate School of Hebei Medical University,Shijiazhuang 050051,China;Department of Cardiology,Hebei General Hospital,Shijiazhuang 050051,China)

机构地区：[1]河北北方学院研究生院,河北省张家口市075000 [2]河北医科大学研究生院,河北省石家庄市050051 [3]河北省人民医院心血管内科,河北省石家庄市050051

出　　处：《实用心脑肺血管病杂志》2023年第8期30-33,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：心力衰竭(HF)的主要病理生理学特征是内皮功能障碍、炎症和氧化应激,尽管经标准治疗后患者HF症状和体征有了极大改善,但射血分数降低的心力衰竭(HFrEF)和射血分数保留的心力衰竭(HFpEF)患者的全因死亡率和住院率依然很高。在一氧化氮(NO)-可溶性鸟苷酸环化酶(sGC)-环鸟苷酸(cGMP)信号通路中,NO可以通过激活sGC而启动该信号通路,产生第二信使cGMP,从而调节血管扩张和血管平滑肌细胞增殖。而sGC刺激剂具有协同NO和直接刺激sGC的双重作用,故其可能作为新型抗HF药物。本研究综述了sGC刺激剂使HF患者获益的证据及相关机制,以期为寻找HF患者新的治疗方法提供参考。The main pathophysiological characteristics of heart failure(HF)are endothelial dysfunction,inflammation and oxidative stress.Although the symptoms and signs of HF have been greatly improved after standard treatment,the all-cause mortality and hospitalization rates in patients with heart failure with reduced ejection fraction(HFrEF)and heart failure with preserved ejection fraction(HFpEF)remain high.In the nitric oxide(NO)-soluble guanylate cyclase(sGC)-cyclic guanylate(cGMP)signaling pathway,NO can activate sGC and start the signaling pathway to produce the cGMP,thereby regulating vasodilation and vascular smooth muscle cell proliferation.The sGC stimulator has the dual effects of synergistic NO and direct stimulation of sGC,so it may be used as a new anti-HF drug.This study reviewed the benefit evidence and related mechanisms of sGC stimulants in HF patients,in order to provide a reference for finding new treatment methods for HF patients.

关 键 词：心力衰竭 可溶性鸟苷酸环化酶 利奥西呱 维利西呱 综述 

分 类 号：R541.6[医药卫生—心血管疾病]